You get a DEXA scan, and a few days later a report arrives with numbers like −1.8 or −2.5. There's no intuitive way to know whether that's reassuring or alarming. Unlike a blood pressure reading or a cholesterol number, bone density scores don't map onto anything most people have encountered before.

Yet these numbers carry real weight. They quantify something you can't feel—the slow, silent loss of bone mineral that raises fracture risk years before a fracture happens. Osteoporosis doesn't announce itself with symptoms. It announces itself with a broken hip or a collapsed vertebra, events that can permanently alter independence and quality of life.

Understanding what a DEXA scan actually measures, how its scoring system works, and what triggers a conversation about treatment turns an opaque lab report into a useful tool. The goal isn't to replace your clinician's interpretation—it's to arrive at that conversation knowing what the numbers mean and what questions to ask.

DEXA stands for dual-energy X-ray absorptiometry. The name reveals its method: two X-ray beams at different energy levels pass through your body simultaneously. Bone absorbs these beams differently than soft tissue does, and the scanner uses that difference to calculate how much mineral—primarily calcium and phosphorus—is packed into a given area of bone.

The result is expressed as bone mineral density, or BMD, measured in grams per square centimeter. It's an areal measurement, not a volumetric one, which means it captures mineral content across a two-dimensional projection of the bone. This is a useful approximation, but it's worth knowing that very large or very small body frames can slightly skew results simply because of bone size.

Clinicians focus on two skeletal sites: the lumbar spine (specifically the L1–L4 vertebrae) and the proximal femur, which includes the femoral neck and total hip. These aren't arbitrary choices. The spine is rich in trabecular bone—the spongy, metabolically active interior tissue that loses mineral fastest. The hip is the site where fractures carry the gravest consequences, including surgical complications and prolonged immobility in older adults.

The scan itself takes about ten to fifteen minutes. You lie on a padded table while a mechanical arm passes overhead. Radiation exposure is remarkably low—roughly one-tenth of a standard chest X-ray. The technology is precise enough to detect changes as small as one to two percent between annual measurements, which matters when you're tracking whether bone loss is accelerating, stabilizing, or responding to treatment.

Takeaway

DEXA doesn't tell you how strong your bones are in every sense—it measures mineral density at the two sites where loss matters most clinically. Think of it as a focused surveillance tool, not a whole-skeleton report card.

Your DEXA report will feature two scores, and they answer fundamentally different questions. The T-score compares your bone density to the average peak bone mass of a healthy 30-year-old of the same sex. Peak bone mass is the highest density your skeleton will ever reach, and it serves as the reference point because fracture risk scales most reliably against that benchmark.

The World Health Organization established clear categories. A T-score of −1.0 or above is considered normal. Between −1.0 and −2.5 is classified as osteopenia—bone density below the ideal range but not yet in the danger zone. A T-score of −2.5 or lower defines osteoporosis. Each standard deviation below zero roughly doubles fracture risk. So a person with a T-score of −2.0 has approximately twice the fracture risk of someone at −1.0.

The Z-score, by contrast, compares your density to the average for people of your same age, sex, and sometimes ethnicity. This score matters most for premenopausal women, men under 50, and children. A Z-score below −2.0 in these groups is flagged as "below expected range for age" and prompts investigation into secondary causes—conditions like celiac disease, hyperparathyroidism, or medication side effects that accelerate bone loss beyond what aging alone explains.

Here's the critical nuance: a T-score might look worse than a Z-score in the same person simply because the reference populations differ. A 70-year-old woman with a T-score of −2.0 might have a Z-score near zero, meaning she's losing bone at the same rate as her peers. The T-score tells you about absolute fracture risk. The Z-score tells you whether something unusual is happening. Both matter, but they serve different diagnostic purposes.

Takeaway

T-scores measure where you stand against the biological ideal. Z-scores measure whether you're falling behind your peers. A worrying T-score with a normal Z-score means aging is doing its work. A worrying Z-score means something else may be driving the loss.

A T-score of −2.5 doesn't automatically mean you'll be prescribed medication, and a T-score of −1.5 doesn't automatically mean you're safe. Treatment decisions layer bone density on top of clinical risk factors, and the tool most widely used to integrate these is called FRAX—the Fracture Risk Assessment Tool developed by the University of Sheffield.

FRAX calculates your ten-year probability of a major osteoporotic fracture (hip, spine, forearm, or shoulder) and your ten-year probability of hip fracture specifically. It factors in age, sex, BMI, prior fractures, parental hip fracture history, smoking status, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, and alcohol intake—alongside your femoral neck BMD. In the United States, pharmacologic treatment is generally recommended when FRAX shows a ≥20% risk of major fracture or ≥3% risk of hip fracture over ten years.

This means two people with identical T-scores can receive different recommendations. A 55-year-old woman with a T-score of −2.0 and no other risk factors might be advised to optimize calcium, vitamin D, and weight-bearing exercise. A 72-year-old woman with the same T-score plus a prior wrist fracture and a mother who broke her hip might be started on a bisphosphonate or another antiresorptive medication immediately.

Beyond medication thresholds, your DEXA results set the tempo for follow-up. If your scores are in the osteopenic range but stable over two consecutive scans, monitoring every two years may suffice. If there's measurable decline between scans—especially a loss exceeding the scanner's least significant change, typically around 3–5% depending on the site—that trajectory itself becomes a reason to intervene, even if you haven't crossed the −2.5 threshold.

Takeaway

Bone density is one input, not the verdict. Treatment decisions emerge from the intersection of your score, your age, your fracture history, and your accumulated risk factors. A single number never tells the whole story—the clinical context around it does.

A DEXA scan gives you a snapshot of mineral density at two critical skeletal sites. The T-score places you on an absolute risk scale. The Z-score tells you whether your rate of loss is expected or unusual. Neither score, on its own, dictates what happens next.

Treatment decisions fold your density numbers into a broader equation of age, fracture history, and cumulative risk. The FRAX tool formalizes this, but the conversation with your clinician is where it becomes personal.

When your next report arrives, look at both scores. Note the trend from any prior scans. Ask where you fall on the FRAX calculator. Those three steps transform a confusing document into a foundation for informed, shared decision-making about your bone health.